Novel human interleukin-15 agonists

Journal of Immunology

Volumn 183, Issue 6, 2009, Pages 3598-3607

  Zhu, Xiaoyun ^a   Marcus, Warren D ^a   Xu, Wenxin ^a   Lee, Hyung Il ^a   Han, Kaiping ^a   Egan, Jack O ^a   Yovandich, Jason L ^b   Rhode, Peter R ^a   Wong, Hing C ^a  

^a ALTOR BIOSCIENCE CORPORATION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CYTOKINE RECEPTOR AGONIST; HYBRID PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKINL 15N72D; JANUS KINASE 1; RECOMBINANT INTERLEUKIN 15; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; JAK1 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DNA HELIX; DRUG POTENTIATION; HUMAN; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS; WILD TYPE; ANIMAL; CELL LINE; DRUG EFFECT; GENETICS; METABOLISM; PHOSPHORYLATION; SPECIES DIFFERENCE;

AMINO ACID SUBSTITUTION; ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; HUMANS; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; JANUS KINASE 1; MICE; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; SPECIES SPECIFICITY; STAT5 TRANSCRIPTION FACTOR;

EID: 70349333236     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901244     Document Type: Article

References (43)

1. Belmont, H. J., S. Price-Schiavi, B. Liu, K. F. Card, H. I. Lee, K. P. Han, J. Wen, S. Tang, X. Zhu, J. Merrill, et al. 2006. Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein. Clin. Immunol. 121: 29-39.
2. Wen, J., X. Zhu, B. Liu, L. You, L. Kong, H. I. Lee, K. P. Han, J. L. Wong, P. R. Rhode, and H. C. Wong. 2008. Targeting activity of a TCR/IL-2 fusion protein against established tumors. Cancer Immunol. Immunother. 57: 1781-1794.
3. Waldmann, T. A. 2006. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6: 595-601. (Pubitemid 44134092)
4. Ma, A., R. Koka, and P. Burkett. 2006. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol. 24: 657-679.
5. Stoklasek, T. A., K. S. Schluns, and L. Lefrancois. 2006. Combined IL-15/IL-15Rα immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177: 6072-6080.
6. high T cells and its antitumor action. J. Immunol. 180: 2099-2106.
7. Epardaud, M., K. G. Elpek, M. P. Rubinstein, A. R. Yonekura, A. Bellemare-Pelletier, R. Bronson, J. A. Hamerman, A. W. Goldrath, and S. J. Turley. 2008. Interleukin-15/interleukin-15Rα complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 68: 2972-2983. (Pubitemid 351556298)
8. Kobayashi, H., J. A. Carrasquillo, C. H. Paik, T. A. Waldmann, and Y. Tagaya. 2000. Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res. 60: 3577-3583. (Pubitemid 30482179)
9. Zamai, L., C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, L. Cocco, and M. Vitale. 2007. NK cells and cancer. J. Immunol. 178: 4011-4016.
10. Lawyer, F. C., S. Stoffel, R. K. Saiki, S. Y. Chang, P. A. Landre, R. D. Abramson, and D. H. Gelfand. 1993. High-level expression, purification, and enzymatic characterization of full-length Thermus aquaticus DNA polymerase and a truncated form deficient in 5′ to 3′ exonuclease activity. PCR Methods Appl. 2: 275-287.
11. Hughes, M. S., Y. Y. Yu, M. E. Dudley, Z. Zheng, P. F. Robbins, Y. Li, J. Wunderlich, R. G. Hawley, M. Moayeri, S. A. Rosenberg, and R. A. Morgan. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16: 457-472.
12. Yang, S., S. A. Rosenberg, and R. A. Morgan. 2008. Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J. Immunother. 31: 830-839.
13. 264-272/HLA-A*0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptor. J. Immunol. 176: 3223-3232.
14. Ruckert, R., K. Brandt, U. Hofmann, S. Bulfone-Paus, and R. Paus. 2002. IL-2-IgG2b fusion protein suppresses murine contact hypersensitivity in vivo. J. Invest. Dermatol. 119: 370-376. (Pubitemid 35001946)
15. Kaspar, M., E. Trachsel, and D. Neri. 2007. The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res. 67: 4940-4948. (Pubitemid 46910202)
16. Chirifu, M., C. Hayashi, T. Nakamura, S. Toma, T. Shuto, H. Kai, Y. Yamagata, S. J. Davis, and S. Ikemizu. 2007. Crystal structure of the IL-15-IL-15Rα complex, a cytokine-receptor unit presented in trans. Nat. Immunol. 8: 1001-1007. (Pubitemid 47300015)
17. Olsen, S. K., N. Ota, S. Kishishita, M. Kukimoto-Niino, K. Murayama, H. Uchiyama, M. Toyama, T. Terada, M. Shirouzu, O. Kanagawa, and S. Yokoyama. 2007. Crystal structure of the interleukin-15-interleukin-15 receptor α complex: insights into trans and cis presentation. J. Biol. Chem. 282: 37191-37204.
18. Johnston, J. A., C. M. Bacon, D. S. Finbloom, R. C. Rees, D. Kaplan, K. Shibuya, J. R. Ortaldo, S. Gupta, Y. Q. Chen, J. D. Giri, and J. J. O'Shea. 1995. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc. Natl. Acad. Sci. USA 92: 8705-8709.
19. Meazza, R., S. Basso, A. Gaggero, D. Detotero, L. Trentin, R. Pereno, B. Azzarone, and S. Ferrini. 1998. Interleukin (IL)-15 induces survival and proliferation of the growth factor-dependent acute myeloid leukemia M-07e through the IL-2 receptor β/γ. Int. J. Cancer. 78: 189-195. (Pubitemid 28443176)
20. Russell, S. M., J. A. Johnston, M. Noguchi, M. Kawamura, C. M. Bacon, M. Friedmann, M. Berg, D. W. McVicar, B. A. Witthuhn, O. Silvennoinen, et al. 1994. Interaction of IL-2R β and γ c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266: 1042-1045.
21. Van Parijs, L., Y. Refaeli, J. D. Lord, B. H. Nelson, A. K. Abbas, and D. Baltimore. 1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11: 281-288.
22. Wang, X., M. Rickert, and K. C. Garcia. 2005. Structure of the quaternary complex of interleukin-2 with its α, β and γ c receptors. Science 310: 1159-1163.
23. Stauber, D. J., E. W. Debler, P. A. Horton, K. A. Smith, and I. A. Wilson. 2006. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc. Natl. Acad. Sci. USA 103: 2788-2793.
24. Pettit, D. K., T. P. Bonnert, J. Eisenman, S. Srinivasan, R. Paxton, C. Beers, D. Lynch, B. Miller, J. Yost, K. H. Grabstein, and W. R. Gombotz. 1997. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. J. Biol. Chem. 272: 2312-2318.
25. Bernard, J., C. Harb, E. Mortier, A. Quemener, R. H. Meloen, C. Vermot-Desroches, J. Wijdeness, P. van Dijken, J. Grotzinger, J. W. Slootstra, A. Plet, and Y. Jacques. 2004. Identification of an interleukin-15α receptor-binding site on human interleukin-15. J. Biol. Chem. 279: 24313-24322.
26. Quemener, A., J. Bernard, E. Mortier, A. Plet, Y. Jacques, and V. Tran. 2006. Docking of human interleukin-15 to its specific receptor α chain: correlation between molecular modeling and mutagenesis experimental data. Proteins 65: 623-636.
27. Studier, F. W., A. H. Rosenberg, J. J. Dunn, and J. W. Dubendorff. 1990. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 185: 60-89.
28. Bamford, R. N., A. J. Grant, J. D. Burton, C. Peters, G. Kurys, C. K. Goldman, J. Brennan, E. Roessler, and T. A. Waldmann. 1994. The interleukin (IL) 2 receptor β chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 91: 4940-4944. (Pubitemid 24177766)
29. + cells. J. Exp. Med. 197: 763-775.
30. Rubinstein, M. P., M. Kovar, J. F. Purton, J. H. Cho, O. Boyman, C. D. Surh, and J. Sprent. 2006. Converting IL-15 to a superagonist by binding to soluble IL-15Rα. Proc. Natl. Acad. Sci. USA 103: 9166-9171.
31. Mortier, E., A. Quemener, P. Vusio, I. Lorenzen, Y. Boublik, J. Grotzinger, A. Plet, and Y. Jacques. 2006. Soluble interleukin-15 receptor α(IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15R β/γ: hyperagonist IL-15 X IL-15Rα fusion proteins. J. Biol. Chem. 281: 1612-1619. (Pubitemid 43752477)
32. Bouchaud, G., L. Garrigue-Antar, V. Sole, A. Quemener, Y. Boublik, E. Mortier, H. Perdreau, Y. Jacques, and A. Plet. 2008. The exon-3-encoded domain of IL-15α contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Rα. J. Mol. Biol. 382: 1-12.
33. Eisenman, J., M. Ahdieh, C. Beers, K. Brasel, M. K. Kennedy, T. Le, T. P. Bonnert, R. J. Paxton, and L. S. Park. 2002. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 20: 121-129. (Pubitemid 35370692)
34. Cornish, G. H., L. V. Sinclair, and D. A. Cantrell. 2006. Differential regulation of T-cell growth by IL-2 and IL-15. Blood 108: 600-608.
35. LaPorte, S. L., Z. S. Juo, J. Vaclavikova, L. A. Colf, X. Qi, N. M. Heller, A. D. Keegan, and K. C. Garcia. 2008. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132: 259-272.
36. Lindemann, M. J., M. Benczik, and S. L. Gaffen. 2003. Anti-apoptotic signaling by the interleukin-2 receptor reveals a function for cytoplasmic tyrosine residues within the common γ (γc) receptor subunit. J. Biol. Chem. 278: 10239-10249.
37. Gaffen, S. L. 2001. Signaling domains of the interleukin 2 receptor. Cytokine 14: 63-77.
38. Cheever, M. A. 2008. Twelve immunotherapy drugs that could cure cancers. Immunol. Rev. 222: 357-368.
39. Chapoval, A. I., J. A. Fuller, S. G. Kremlev, S. J. Kamdar, and R. Evans. 1998. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J. Immunol. 161: 6977-6984.
40. Wysocka, M., B. M. Benoit, S. Newton, L. Azzoni, L. J. Montaner, and A. H. Rook. 2004. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 104: 4142-4149. (Pubitemid 39620167)
41. + T cells. Proc. Natl. Acad. Sci. USA 101: 1969-1974.
42. + T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12: 335-341.
43. Evans, R., J. A. Fuller, G. Christianson, D. M. Krupke, and A. B. Troutt. 1997. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell Immunol. 179: 66-73. (Pubitemid 27360105)